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Objective: The aim of this study was to identify the most sensitive heart rate and blood
pressure variability (HRV and BPV) parameters from a given set of well-known methods
for the quantification of cardiovascular autonomic function after several autonomic
blockades.
Methods: Cardiovascular sympathetic and parasympathetic functions were studied
in freely moving rats following peripheral muscarinic (methylatropine), β1-adrenergic
(metoprolol), muscarinic + β1-adrenergic, α1-adrenergic (prazosin), and ganglionic
(hexamethonium) blockades. Time domain, frequency domain and symbolic dynamics
measures for each of HRV and BPV were classified through paired Wilcoxon test for all
autonomic drugs separately. In order to select those variables that have a high relevance
to, and stable influence on our target measurements (HRV, BPV) we used Fisher’s Method
to combine the p-value of multiple tests.
Results: This analysis led to the following best set of cardiovascular variability
parameters: The mean normal beat-to-beat-interval/value (HRV/BPV: meanNN), the
coefficient of variation (cvNN = standard deviation over meanNN) and the root mean
square differences of successive (RMSSD) of the time domain analysis. In frequency
domain analysis the very-low-frequency (VLF) component was selected. From symbolic
dynamics Shannon entropy of the word distribution (FWSHANNON) as well as POLVAR3,
the non-linear parameter to detect intermittently decreased variability, showed the best
ability to discriminate between the different autonomic blockades.
Conclusion: Throughout a complex comparative analysis of HRV and BPV measures
altered by a set of autonomic drugs, we identified the most sensitive set of informative
cardiovascular variability indexes able to pick up the modifications imposed by the
autonomic challenges. These indexes may help to increase our understanding of
cardiovascular sympathetic and parasympathetic functions in translational studies of
experimental diseases.
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INTRODUCTION
Heart rate (HR) and blood pressure (BP) continuously fluctuate
over time under the influence of control mechanisms such as
autonomic nerve activity, humoral factors, and respiration for
maintaining cardiovascular homeostasis. The investigation of
heart rate and blood pressure variability (HRV and BPV) has
become increasingly popular for the assessment of autonomic
nervous system (ANS) such as autonomic tone, sympathovagal
balance, or vagal function (Campos et al., 2013) in health and
disease (Carthy, 2014). Various means of variability analysis
have been employed such as time domain and frequency
domain or linear and non-linear behaviors in order to find the
HRV and BPV measures that could characterize best the ANS
function in disease (Campos et al., 2013). For this, translational
cardiovascular variability studies in controlled physiological
conditions with pharmacological manipulation of the ANS
function at different levels are necessary.
Time domain parameters are usually based on simple
statistical methods; they are derived from the RR-intervals
and their variations (Draghici and Taylor, 2016). The mean
HR is the simplest parameter, but the respective standard
deviation obtained from the whole-time series (sdNN) is the
most prominent HRV measure for estimating overall HRV. The
overall HRV estimate sdNN and other time domain parameters
can be used to predict mortality in the recovery period after
a myocardial infarction. A robust method to quantify the RR-
distribution based on information theory is the Shannon entropy
of the histogram.
Frequency domain HRV parameters allow the analysis of
periodic dynamics in the HR time series (Draghici and Taylor,
2016). There are different techniques for spectral analysis:
(1) methods based on Fast Fourier Transform (FFT) (Cerutti
et al., 1991), (2) parametric autoregressive model estimation
techniques (Rubini et al., 1993), and (3) wavelet approaches (Tsai
et al., 2004; Neto et al., 2016). The results using different spectral
methods, however, should be comparable (apart from differences
in time and frequency resolution). The Task Force on HRV
(Malik et al., 1996) recommends that power spectral analysis
of 5-min ECG recordings should be used to assess autonomic
physiology and pharmacology. The power within different
frequency bands (see Table 1) can be estimated from such ECG
recording. The high frequency power reflects modulation of
vagal activity by respiration whereas the low frequency power
represents vagal and sympathetic activity via the baroreflex
loop. The low-to-high frequency ratio is used as an index of
sympathovagal balance. Cross and slope 1/f denote the zero-
crossing as well as the slope of the 1/f power-law scaling. For
blood pressure (BP) analysis, all parameters described for HRV
can be calculated for systolic blood pressure (SBP) and diastolic
blood pressure (DBP) accordingly.
HRV and BPV reflect the complex interactions of many
different control loops of the cardiovascular system. In relation
to the complexity of the sinus node activity modulation system, a
predominantly non-linear behavior has to be assumed. Thus, the
detailed description and classification of dynamic changes using
time and frequency measures is often not sufficient. Therefore,
TABLE 1 | Description of time domain and frequency domain parameters.
Variable Units Definition
TIME DOMAIN STATISTICAL METHODS
meanNN ms or mmHg Mean BBI or mean blood pressure (BP)
sdNN ms or mmHg Standard deviation of all BBI or BP values
sdaNN1 ms or mmHg standard deviation of 1-min averages
cvNN None sdNN/meanNN
RMSSD ms or mmHg Root mean square of successive BBI or
BP differences
pNNlX (•) % Percentage of beat-to-beat differences
lower than X ms (mmHg) [e.g., X =
3/6/9/12 ms (mmHg)]
shannon (•) None Shannon entropy of the histogram (density
distribution of the BBIs or BP values)
FREQUENCY DOMAIN METHODS
P ms2 or mmHg2 Total power from 0−0.4 Hz
ULF ms2 or mmHg2 Ultra low frequency band 0−0.05 Hz
VLF ms2 or mmHg2 Very low frequency band 0.05−0.18 Hz
ULF+VLF ms2 or mmHg2 Frequency band 0−0.18 Hz
LF ms2 or mmHg2 Low frequency band 0.18-1 Hz
HF ms2 or mmHg2 High frequency band 1-2 Hz
LF/HF None Quotient of LF and HF
HFn None Normalized high frequency band
[HF/(LF+HF)]
LFn None Normalized low frequency band
[LF/(LF+HF)]
Adopted standards (Malik et al., 1996) and additional measures indicated by (•) are listed.
BBI refers to the filtered beat-to-beat intervals (NN-intervals).
new methods of non-linear dynamics derived from the symbolic
dynamics to distinguish between different states of the autonomic
interactions were introduced (Voss et al., 1996; Wessel et al.,
2007a). We and others have shown that tools from non-linear
dynamics may improve the diagnosis in clinical conditions, such
as a risk stratification for sudden cardiac death, forecasting
of life-threatening cardiac arrhythmias, atrial fibrillation after
cardiac surgery, congestive heart failure (reviewed in Wessel
et al., 2007a).
Here, we aimed at investigating the cardiovascular variability
indices relative to the sympathetic and parasympathetic
components of ANS and identifying the most sensitive of them.
Classical and newer variability analyses in time and frequency
domains were applied to heart rate and blood pressure variability
responses evoked by pharmacological manipulation of ANS.
METHODS
All procedures complied with guidelines from the American
Physiological Society, and the institutional ethical committee
approved the study (Camilo Castelo Branco University Ethical
Committee approval no. 0021/2013).
Male Sprague-Dawley (SD) rats (12–14 weeks of age) were
used for the study. Following acclimatization and a health
examination, rats were housed in groups of three in standard
cages with wire mesh tops and standardized softwood bedding,
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synchronized to a 12-h light–dark cycle, at ambient temperature
23 ± 2◦C. A standard rat diet and tap water were supplied
ad libitum. The rats underwent implantation of polyethylene
catheters (PE-50; filled with 10 IU/ml heparinized saline) that
were inserted into the femoral artery (tomonitor arterial pressure
and heart rate) and femoral vein (for i.v. injection of drugs) and
exteriorized in the interscapular area and housed individually,
as previously described (Baltatu et al., 2001). At least 48 h were
allowed between the catheter implant and the experiment. Six rats
per group for each drug were used.
All experimental protocols were performed between 2 and 4
pm (the period with lowest activity) in conscious, unrestrained
and unstressed animals housed in individual cages. The
experimental phase of the study investigated the effects of the
following autonomic blockers at doses previously established to
cause a BP or HR effect: Peripheral muscarinic (methylatropine,
0.5 mg/kg) (Woods et al., 1994), β1-adrenergic (metoprolol, 1
mg/kg) (Webb et al., 1991; Pham et al., 1993), α1-adrenergic
(prazosin, 1 mg/kg) (Kurnjek et al., 1983; Pham et al., 1993),
and ganglionic (hexamethonium, 10 mg/kg) (Gao et al., 1997)
blockades. The effectiveness of the dosing (in 0.1 mL volume
of injection) was shown through a sustained effect on heart
rate or blood pressure. The measurements of BP and HR
were performed with the catheter connected to a standard
blood pressure transducer that was coupled to a PowerLab and
recorded with LabChart 8 software (ADInstruments, Sydney,
Australia). Intrafemoral blood pressure was sampled at 4 kHz to
generate evenly spaced signals to monitor the arterial pressure
and heart rate. Online monitoring was performed using Blood
Pressure Module for LabChart software that automatically
detects, analyzes and reports cardiovascular parameters from
arterial pressure signals, including systolic/diastolic BP and beat-
to-beat intervals (BBI, or NN-intervals detected automatically
from maximal values of the BP oscillations). After recording a
stable baseline period (30min of stable hemodynamics), the drug
was injected and further beat-to-beat measurements of BP and
HR were performed for 60 min when the drug effect reached its
peak (peak-time) in a plateau with stabilized hemodynamics.
Cardiovascular Variability Analyses
The calculation of all variability parameters was performed on
time series derived from the original blood pressure signal as
described in Wessel et al. (2007b). Missing beats and erroneous
detections were eliminated using the adaptive filter described
in Wessel et al. (2007a). Standard methods of HRV and BPV
analysis including time domain as well as frequency domain
parameters were obtained; most of them are based on linear
methods. A list of these parameters is given in Table 1. The
selection of these parameters was based on the idea that one
should always use the simplest and best understoodmethods first.
The first step of non-linear dynamics derived from the
symbolic dynamics is the transformation of the time series
into symbol sequences using symbols from a given alphabet.
Certainly, some of the detail information is lost in this
thresholding process, but the coarse dynamic behavior is
retained. Comparing different kinds of symbol transformations,
we found that the use of four symbols, as explained in Equation
(1), was appropriate for our purpose. The time series x1, x2, x3,...,
xN is transformed into the symbol sequence s1, s2, s3,..., sN , si ∈A
on the basis of the alphabet A = [0,1,2,3]. The transformation
into symbols by Equation (7) refers to 4 given amplitude ranges
whereµ denotes the mean beat-to-beat interval and a is a specific
parameter which is heuristically determined.
si(xi) =


0: µ < xi ≤ (1+ a)µ
1: (1+ a)µ < xi < ∞
2: (1− a)µ < xi ≤ µ
3: 0 < xi ≤ (1− a)µ
with i = 1, 2, 3, ... (1)
Note, that the order of the symbols in formula (1) is of no
relevance. There are several quantities that characterize such
symbol strings. Analyzing words of length 3 (i.e., substrings
which consist of three adjacent symbols) leads to a maximum of
43 = 64 different words (bins). This word length is a compromise
between retaining important dynamical information and having
robust statistics, when estimating the probability distribution
of the words. The Shannon entropy Hk calculated from the
distribution p of words is the classic measure “FWShannon” for
the complexity in time series:
Hk = −
∑
ω∈Wk ,p(ω)>0
p(ω) log p(ω) (Malik et al., 1996)
where Wk is the set of all words of length k. Larger values of
Shannon entropy refer to higher complexity in the corresponding
tachograms and lower values to lower ones. “Forbidden words”
(FORBWORD) in the distribution of words of length 3 are those
words that never (or almost never) occur. A high number of
forbidden words reflects a rather regular behavior in the time
series. If the time series is highly complex in the Shannonian
sense, only a few forbidden words are found. WPSUM02
(WPSUM13) denotes the percentage of words consisting only of
the symbols “0” or “2” (“1” or “3”). WSDVAR is the overall word
variability (Voss et al., 1996).
The parameter ’POLVAR3’ characterizing short phases of
low variability from successive symbols is determined by using
another simplified alphabet B which consists of symbols “0”
and “1,” only. Here “0” stands for a small difference between
two successive values, whereas “1” represents cases when the
difference between two successive data points exceeds a certain
limit δ, specifically
sn =
{
1: |xn − xn−1| ≥ δ
0: |xn − xn−1| < δ.
with n = 1, 2, 3, ... (2)
Words consisting of a unique type of symbols (either all “0” or
all “1”) are counted. To obtain a statistically robust estimate of
the word distribution, words of length six, defining a maximum
of 64 different words were chosen. “POLVAR3” represents the
probability of the word “000000” occurrence and thus detects
even intermittently decreased variability.
Statistical Analysis
Statistics were performed using R. Our initial test was aWilcoxon
paired test with a null hypothesis that there is no change between
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baseline and peak-time for the combination of measurement
and calculated parameter. In order to select those variables that
have a high relevance to, and stable influence on our target
measurements (HRV, SBP, DBP) we used FisherÕs Method to
combine the p-value of multiple tests. According to Fisher,
the sum of the logarithms of the p-value times 2 is again χ2
distributed with 2∗‘number of p-values’ degrees of freedom, so
that we can again calculate a combined p-value.
RESULTS
To show significant influences of the individual drugs on the
cardiovascular variables we used standard analytical methods of
time and frequency analysis (Malik et al., 1996) as well as from
symbolic dynamics. Performing the statistical analysis described
above we obtained 6 parameters that showed the biggest impact
over all treatments between basal and peak time (cf. Figure 1).
The best set of measures were:
i. FWSHANNON, the Shannon entropy of the word
distribution,
ii. meanNN, the mean beat-to-beat interval or mean blood
pressure,
iii. VLF, the very low frequency component of frequency domain
analysis,
iv. POLVAR3, symbolic dynamics parameter to detect decreased
variability,
v. cvNN, the ratio of sdNN and meanNN and
vi. RMSSD, the root mean square differences of successive
values.
As one can see from Figure 1, the biggest differences were
found in HRV, more than half of the parameters were below
the significance level of 0.01. The HRV complexity quantified
by FWSHANNON showed the biggest differences between all
blockades, however, the mean HR and BP values were highly
significant, too. The VLF frequency band was significant for HRV
and BPV. POLVAR3 was significant for HRV and DBP only,
corresponding to a decreased HRV (<3ms) and to a decreased
diastolic BP variability (<3mmHg). cvNN and RMSSD showed
significant differences for HRV only.
Methylatropine affected mean HR and HRV, with an increase
of POLVAR3 whereas all other parameters decreased due to
decreased HRV (Table 2). Methylatropine had no effect on BP.
For metoprolol, while the mean HR was not significantly altered,
the HRV complexity and VLF component decreased. Metoprolol
did not affect BPV although there was a decrease in mean BP.
The combination of methylatropine with metoprolol led to a
decreased mean HR. Moreover, the HRV complexity, VLF and
POLVAR3 strongly decreased.
Prazosin was the only drug affecting significantly both HR
and BP: Mean HR decreased, BP dropped, HRV complexity
decreased, the VLF component fell down for both HRV and BPV
and we saw a strong decrease in HRV and DBP (increase in
POLVAR3).
Hexamethonium led to a drop in BP not affecting the mean
HR, to a decreased VLF component in HRV and BPV and to a
decrease in HRV (POLVAR3).
In Figure 2 the basal and peak time values for the top 3
parameters: MeanNN, VLF, and POLVAR3 for all six blockades
and all domains HRV, SBP, and DBP are shown. MeanNN
represents the average changes in HR and BP, VLF, and POLVAR3
quantify intermittently decreased variability.
DISCUSSION
The present study provides the most sensitive measures of
ANS function in rats that may best serve as biomarkers of
ANS alterations in further translational studies. Throughout a
complex comparative analysis of HRV and BPVmeasures altered
by a set of autonomic drugs, we identified the most sensitive
set of informative cardiovascular variability indexes able to pick
up the modifications imposed by the autonomic challenges.
These indexes may help to increase our understanding of
cardiovascular sympathetic and parasympathetic functions in
translational studies of experimental diseases. The Shannon
entropy of the word distribution FWSHANNON and the
symbolic dynamics parameter POLVAR3 appear as very sensitive
measures to detect alterations in HR or BP variability induced
by the ANS. Also, we do not expect that single measure can
serve as a reliable biomarker for different complex diseases
with overlapping (e.g., cardiovascular) symptomatology and
this should be addressed in further studies. Instead, we
aimed at identifying the most sensitive analytical method that
could be used to detect the blockade of the specific arm of
the ANS.
Symbolic dynamics has been applied to assess the autonomic
cardiovascular regulation in men (Voss et al., 1996; Guzzetti
et al., 2005) and experimental animals (Tobaldini et al., 2009a).
Symbolic dynamics appears as more adequate than spectral
analysis to analyze dynamic complexity of HRV in interpreting
the complexity of short-term heart-period sequences in rats
(Tobaldini et al., 2009b). It has been demonstrated in rats that
symbolic analysis is a more sensitive tool than spectral analysis
to track the changes in cardiovascular autonomic modulation
(Tobaldini et al., 2009a). Symbolic analysis of SBP variability
is consistent with those derived from HRV (Tobaldini et al.,
2009a). There are further studies using symbolic analyses in
animal models (Wernicke et al., 2007; Wessel et al., 2007b). A
complete overview of all currently available symbolic parameters
and a quantification of their interrelationship and dependence
on certain medications were outside the scope of this paper.
Our study indicates that symbolic dynamics derived parameter
POLVAR3 and Shannon entropy of the word distribution
FWSHANNON are sensitive measures of HR and BP variability
to detect alterations in autonomic cardiovascular regulation in
rats. In men, these profiles may be different due to the regular,
periodic action of respiratory rhythm and to a more complex
cardiovascular control at long time scales (Ho et al., 2011; Silva
et al., 2016). Further studies shall certify whether HRV data
in rats are equivalent homologous surrogates of cardiovascular
morbidity and mortality (Farraj et al., 2011).
Alterations of the ANS tone during cardiac parasympathetic
blockade were associated with a significant increase of the
average HR. The ANS control of the heart rate has normally the
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FIGURE 1 | The ability of different HRV, SBP, and DBP parameters to discriminate between the different autonomic blockades. The significance levels
shown below are achieved by the statistical analysis described in the respective section. The lower the p-value, the higher are the differences of the physiological
parameter between the several blockades.
TABLE 2 | Set of the six best parameters showing the biggest impact over
all treatments between basal and peak time.
Medication
(HRV/BP)
FWSHANNON VLF POLVAR3 cvNN meanNN RMSSD
Methylatropine −−/0 −−/0 ++/0 −/0 −/0 −−/0
Metoprolol −/0 −−/0 0/0 0/0 ++/0 0/0
Methylatropine
+ Metropolol
−−/0 −−/0 ++/0 −/0 +/0 0/0
Prazosin −−/0 −−/−− ++/++(D) −/0 ++/−− −−/0
Hexamethonium −/0 −−/− +/0 −/0 0/−− −/0
Symbols: Big increase (++), increase (+), no change (0), decrease (−), big decrease
(–). Changes for only one value of the diastolic (D) blood pressure are labeled
(Prazosin/polvar3).
parasympathetic (cholinergic) component dominant, meaning
that the heart is under a tonic vagal activity. Therefore, the
vagolytic activity of anticholinergic drugs causes an increase
in heart rate and is used against sinus bradycardia and AV
nodal block due to excessive vagal activation. Administration
of atropine is the common method to investigate tonic vagal
activity. Spectral analysis of HRV has shown that anticholinergic
drugs generally decrease the HF power of HR and blood
pressure variability in humans (Pomeranz et al., 1985; Parlow
et al., 1997). While low doses of atropine cause a decrease in
HR and an increase in HRV, higher doses cause an increase
in HR and a decrease in HRV (reviewed in Lewis et al.,
2006). These antagonizing cardiac effects of atropine occur
since it can cross the blood-brain barrier and induce a central
anticholinergic syndrome (Rupreht et al., 1983). In our study,
we used methylatropine that is an exclusive peripheral antagonist
that blocks the cardiac muscarinic receptors (M2) found mainly
in sinoatrial node (Smith et al., 1994). Pharmacodynamics’ data
of methylatropine denote its higher vagolytic potency with a
longer effect than atropine (Stoll, 1948; Jansen and Dellinger,
1989). In our study, methylatropine significantly affected the
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FIGURE 2 | The basal and peak time values for meanNN, VLF, and POLVAR3 for all five blockades and all domains (HRV, SBP, DBP).
mean HR (increase) and HRV, without affecting BP. Of these
HRV parameters, the best to characterize an inhibition of vagal
tone was FWSHANNON, VLF, and RMSSD decrease, associated
with a POLVAR3 increase.
The β-adrenoceptor antagonists (or β-blockers) are a class
of sympatholytic drugs used for treating hypertension, angina,
myocardial infarction, arrhythmias and heart failure (Frishman,
2008; Poirier and Tobe, 2014). Most of the studies on the
cardiac autonomic effects of β-adrenoceptor antagonism in these
cardiovascular diseases aimed at augmenting parasympathetic
input through a reduction in sympathetic activity. These ANS β-
blocker effects are largely acknowledged to be “cardioprotective”
by decreasing the force and rate of myocardial contraction
and renin secretion. To investigate the effects of sympathetic
inhibition on HRV in our study we utilized metoprolol that
is a β1-selective (cardioselective) adrenergic receptor blocker.
Metoprolol acting on β1- adrenoceptors found in sinoatrial node
slows the heart rate. In our study, the β-adrenergic blockade
significantly decreased HR, and the VLF component of HRV.
The α1-adrenergic antagonists are exercising antihypertensive
action by directly relaxing arterial and venous smooth muscle,
and are used as adjuvant therapy in hypertension. Recent
evidence is suggesting a cardioprotective role of α1-adrenergic
receptors in the heart function in congestive heart failure (in
the ALLHAT clinical trial, the arm of the trial using α1-blocker
doxazosin had to be stopped because of higher number of
heart failure events) (Cotecchia et al., 2015). Thus, the role and
mechanisms of the “augmented of α-adrenergic tone in heart
failure” (Leier et al., 1990) needs further investigation. In our
study, prazosin was the only autonomic drug affecting both HR
and BP levels. Acute blockade of the α-adrenergic tone with
prazosin decreased blood pressure and increased heart rate. This
was accompanied by a big drop of HRV and BPV complexity, as
depicted by the increase of POLVAR3.
Ganglionic blockers were used in 1940s for “autonomic
nervous system denervation” in resistant hypertension but they
have been replaced due to their postural hypotension effect
(DeQuattro and Li, 2002; D’Elia and Weinrauch, 2013). Of
those, hexamethonium is a nicotinic cholinergic antagonist
that does not cross the blood-brain barrier and is referred as
prototype ganglionic blocker. Symptoms resembling ganglionic
blockade occur in the autoimmune autonomic ganglionopathy
(AAG), a rare disease (Garland et al., 2013). In our study,
hexamethonium lowered mean BP without affecting mean HR.
This was accompanied with a drop of VLF and HRV complexity
and an increase of POLVAR3.
Some limitations of the present study must be addressed.
While the HRVwas calculated from the blood pressure curve and
not from ECG, we showed that there is only a limited difference
between the two methods of data acquisition (Suhrbier et al.,
2006). In this study, the VLF spectral power from heart rate
variability signal has been shown to be a sensitive marker of
the autonomic nervous system activity (overcoming LF and HF
spectral powers). However, while the origin and the significance
of these oscillations are currently not completely understood,
the results of our study can inform and should motivate further
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studies. Among the studied variability parameters, we observed
that there was a decrease in time of the mean values and inter-
individual variability of VLF SBP that could be explained through
a recovery in time from the catheter implantation surgery or
an adaptation of the animal to the experimental protocol. Also,
this trend does not appear in any other parameters investigated.
Besides, since the drug administration was in a given order, it
could be thought that it might be a residual effect from the
previous drug administration. However, the drugs have short
half-lives (longest is 3 h) and 24 h between dosing allows a
wash-out of the previous drug administration. Nevertheless, this
should not affect the outcome of this study, as only the difference
between basal and peak time was relevant.
In summary, we detected the most sensitive variability
analysis derived measures of HR and BP after pharmacological
modification of autonomic nervous system activity in rats.
The translation of the findings from rats to human is not
straightforward. The different basal setting of the ANS in rats
should be taken into consideration in this process. As such
species-specific differences include for instance the cardiovagal
activity that is highest during inspiration in rats, while in humans
it is inhibited (Draghici and Taylor, 2016). Further translational
studies to assess ANS using these cardiovascular variability
biomarkers in clinical practice are envisaged.
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